Download PDF
Int J Angiol
DOI: 10.1055/s-0044-1788069
Original Article

Association of ET1 and APE1 Genes Polymorphism with Coronary Artery Disease

Syed T. Raza
1   Department of Biochemistry, Era's Lucknow Medical College and Hospital Lucknow, Uttar Pradesh, India
,
Ale Eba
1   Department of Biochemistry, Era's Lucknow Medical College and Hospital Lucknow, Uttar Pradesh, India
,
Irshad A. Wani
2   Department of Medicine (Cardiology Unit), Era's Lucknow Medical College and Hospital Lucknow, Uttar Pradesh, India
,
Sanchita Srivastava
1   Department of Biochemistry, Era's Lucknow Medical College and Hospital Lucknow, Uttar Pradesh, India
,
Farzana Mahdi
3   Department of Personalized Medicine, Era University Lucknow, Uttar Pradesh, India
› Author Affiliations Funding None.
› Further Information
    Permissions and Reprints

Abstract

Coronary artery disease (CAD) is one of the most common cardiovascular diseases (CVDs), being the foremost reason for mortality and disability globally. It is a cascade of polygenic architecture of various disorders as a resultant of complexities between various genetic factors and environmental factors. The aim of the present study was to investigate whether the ET1 and APE1 gene polymorphism is associated with the susceptibility to CAD. This study was approved by the Ethical Review Committee of Era Medical College and Hospital. Three milliliters of venous blood sample was collected in ethylenediaminetetraacetic acid-coated vials, and genomic DNA was isolated by using the standard phenol-chloroform extraction method for restriction fragment length polymorphism-polymerase chain reaction study. The APE1 gene AA, AG, GG, and AG + GG genotypes frequencies were 13.91, 40.87, 45.22, and 86.99% in CAD cases and 13, 50, 37, and 87% in controls, respectively. The ET1 gene GG, GT, TT, GT + TT genotypes frequencies were 6.67, 37.5, 55.8, and 93.34% in CAD cases and 6.67, 25.33, 68, and 93.34% in controls. The ET1 and APE1 gene polymorphisms were not significantly associated with the risk of CAD.

Keywords

coronary artery disease - endothelin 1 - apurinic/apyrimidinic endonuclease 1 - gene polymorphism

Authors' Contributions

S.T.R. have done overall search and compilation of data. I.A.W. helped in the collection of sample. A.E. helped in the analysis of data. S.S. wrote the manuscript. F.M. has done overall supervision. All authors read and approved the final manuscript.


Ethical Approval

Protocol and procedures in the study complied with the declaration of Institutional Ethical/ Review Committee (Ref no. ELMC &H/R-Cell-/2019/24) of Era's Lucknow Medical College and Hospital, Lucknow.




Publication History

Article published online:
04 July 2024

© 2024. International College of Angiology. This article is published by Thieme.

Thieme Medical Publishers
333 Seventh Avenue, New York, NY 10001, USA.

 

  • References

  • 1 Raza ST, Singh SP, Rizvi S. et al. Association of eNOS (G894T, rs1799983) and KCNJ11 (E23K, rs5219) gene polymorphism with coronary artery disease in North Indian population. Afr Health Sci 2021; 21 (03) 1163-1171
    CrossrefPubMedGoogle Scholar
  • 2 Raza ST, Abbas S, Eba A. et al. Association of COL4A1 (rs605143, rs565470) and CD14 (rs2569190) genes polymorphism with coronary artery disease. Mol Cell Biochem 2018; 445 (1-2): 117-122
    CrossrefPubMedGoogle Scholar
  • 3 Eba A, Raza ST, Abbas M, Rizvi S, Rajput M, Mahdi F. Association of SDF1β (G801A) and GNB3 (C825T) polymorphisms with the incidence and severity of coronary artery disease. Br J Biomed Sci 2019; 76 (01) 49-51
    CrossrefPubMedGoogle Scholar
  • 4 Arnett DK, Baird AE, Barkley RA. et al; American Heart Association Council on Epidemiology and Prevention, American Heart Association Stroke Council, Functional Genomics and Translational Biology Interdisciplinary Working Group. Relevance of genetics and genomics for prevention and treatment of cardiovascular disease: a scientific statement from the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 2007; 115 (22) 2878-2901
    CrossrefPubMedGoogle Scholar
  • 5 Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365 (9455): 217-223
    CrossrefPubMedGoogle Scholar
  • 6 Pradeepa R, Anjana RM, Joshi SR. et al; ICMR-INDIAB Collaborative Study Group. Prevalence of generalized & abdominal obesity in urban & rural India—the ICMR-INDIAB Study (Phase-I) [ICMR- NDIAB-3]. [ICMR- INDIAB3] Indian J Med Res 2015; 142 (02) 139-150
    CrossrefPubMedGoogle Scholar
  • 7 Maguire JJ, Davenport AP. Endothelin receptors and their antagonists. Semin Nephrol 2015; 35 (02) 125-136
    CrossrefPubMedGoogle Scholar
  • 8 Peto H, Corder R, Janes RW, Wallace BA. A molecular model for human Big-Endothelin-1 (Big ET-1). FEBS Lett 1996; 394 (02) 191-195
    CrossrefPubMedGoogle Scholar
  • 9 Tell G, Quadrifoglio F, Tiribelli C, Kelley MR. The many functions of APE1/Ref-1: not only a DNA repair enzyme. Antioxid Redox Signal 2009; 11 (03) 601-620
    CrossrefPubMedGoogle Scholar
  • 10 Thakur S, Sarkar B, Cholia RP, Gautam N, Dhiman M, Mantha AK. APE1/Ref-1 as an emerging therapeutic target for various human diseases: phytochemical modulation of its functions. Exp Mol Med 2014; 46 (07) e106
    CrossrefPubMedGoogle Scholar
  • 11 Naganuma T, Nakayama T, Sato N. et al. Haplotype-based case-control study on human apurinic/apyrimidinic endonuclease 1/redox effector factor-1 gene and essential hypertension. Am J Hypertens 2010; 23 (02) 186-191
    CrossrefPubMedGoogle Scholar
  • 12 Zhang Y, Wang J, Xiang D, Wang D, Xin X. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE1/Ref-1) in human ovarian cancer and indentification of the therapeutic potential of APE1/Ref-1 inhibitor. Int J Oncol 2009; 35 (05) 1069-1079
    PubMedGoogle Scholar
  • 13 Botto N, Rizza A, Colombo MG. et al. Evidence for DNA damage in patients with coronary artery disease. Mutat Res 2001; 493 (1-2): 23-30
    CrossrefPubMedGoogle Scholar
  • 14 Mahmoudi M, Mercer J, Bennett M. DNA damage and repair in atherosclerosis. Cardiovasc Res 2006; 71 (02) 259-268
    CrossrefPubMedGoogle Scholar
  • 15 Martinet W, Knaapen MW, De Meyer GR, Herman AG, Kockx MM. Elevated levels of oxidative DNA damage and DNA repair enzymes in human atherosclerotic plaques. Circulation 2002; 106 (08) 927-932
    CrossrefPubMedGoogle Scholar
  • 16 Paralkar V, Wistow G. Cloning the human gene for macrophage migration inhibitory factor (MIF). Genomics 1994; 19 (01) 48-51
    CrossrefPubMedGoogle Scholar
  • 17 Schiffrin EL. Vascular endothelin in hypertension. Vascul Pharmacol 2005; 43 (01) 19-29
    CrossrefPubMedGoogle Scholar
  • 18 Forouzanfar MH, Liu P, Roth GA. et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990–2015. JAMA 2017; 317 (02) 165-182
    CrossrefPubMedGoogle Scholar
  • 19 Parrinello G, Scaglione R, Pinto A. et al. Central obesity and hypertension: the role of plasma endothelin. Am J Hypertens 1996; 9 (12 Pt 1): 1186-1191
    CrossrefPubMedGoogle Scholar
  • 20 Tu G, Fang Z, Zhao Y, Wu Q. Association of +138I/D and Lys198Asn polymorphisms in the endothelin-1 gene with early onset of coronary artery disease among the Chinese Han population. Med Sci Monit 2020; 26: e921542
    PubMedGoogle Scholar
  • 21 Ebrahimi N, Asadikaram G, Mohammadi A, Jahani Y, Moridi M, Masoumi M. The association of endothelin-1 gene polymorphism and its plasma levels with hypertension and coronary atherosclerosis. Arch Med Sci 2019; 17 (03) 613-620
    CrossrefPubMedGoogle Scholar
  • 22 Popov AF, Schulz EG, Hinz J. et al. Impact of endothelin-1 Lys198Asn polymorphism on coronary artery disease and endorgan damage in hypertensives. Coron Artery Dis 2008; 19 (07) 429-434
    CrossrefPubMedGoogle Scholar
  • 23 Gregoski MJ, Buxbaum SG, Kapuku G. et al. Interactive influences of ethnicity, endothelin-1 gene, and everyday discrimination upon nocturnal ambulatory blood pressure. Ann Behav Med 2013; 45 (03) 377-386
    CrossrefPubMedGoogle Scholar
  • 24 Tekeli A, Isbir S, Ergen A. et al. APE1 and XRCC3 polymorphisms and myocardial infarction. In Vivo 2008; 22 (04) 477-479
    PubMedGoogle Scholar